INTRODUCTION
Breast cancer is the second most common cancer and the sixth leading cause of cancer deaths in women in Korea.
Neoadjuvant therapy, surgery, and adjuvant therapy are standard treatments for locally advanced breast cancer.
Typically, neoadjuvant therapy plays an important role in patients with locally advanced breast cancers and in treating distant micrometastasis, downstaging tumors, improving operability, and sometimes in allowing breast thesurgery.or.kr conserving surgery (BCS). The multidisciplinary management approach combined with neoadjuvant chemotherapy (NAC) and the incorporation of anthracyclines and taxanes has resulted in a significant reduction in the risk of death and a subsequent reduction in the 5-year recurrence rate for patients with early and advanced stage breast cancers [1, 2] .
NAC was first introduced in the 1970s [3] and several clinical studies since then have corroborated the efficacy of NAC [4, 5] . A majority of studies report that after NAC, the partial response rate was 60% to 80% and the complete response (CR) rate was 10% to 20% [5, 6] . The primary goals of NAC are to increase the rate of BCS and to predict prognosis through the response of tumors to treatment [7, 8] .
On the other hand, studies have estimated that approximately 20% to 25% of invasive breast cancers exhibit overexpression and gene amplification of human epidermal growth factor receptor-2 (HER2, also known as ERBB2) [9, 10] . This represents an adverse prognostic indicator associated with aggressive histopathologic parameters and is correlated with decreased recurrence-free survival (RFS), overall survival (OS), and poor prognosis and outcome.
Trastuzumab, a monoclonal antibody directed against HER2, has become a standard treatment in HER2 positive breast cancer patients and has resulted in increased remission rates after neoadjuvant therapy [11] . Given the improvement in outcomes with the neoadjuvant use of trastuzumab with HER2 positive breast cancer patients, the optimal use of these compounds is still unclear. A number of new treatment approaches directed against HER2 are currently being examined in clinical trials. The purpose of this retrospective study was to assess pathologic CR (pCR), RFS, and OS rates in patients treated with NAC combined with neoadjuvant HER2 targeted therapy (NCHTT) compared to patients treated with NAC only. 19.4%, P ＜ 0.001). All 28 patients treated with NCHTT showed normal cardiac function before and after chemotherapy (Table 2 ). There were no significant differences in tumor size, nodal status, receptor status or hormone therapy use between the two groups.
METHODS
During the median follow-up of 28.7 months (range, 5.7
to 70.0 months), seven patients experienced disease re-thesurgery.or.kr currence; interestingly, all were from the NAC only group.
The 3-year RFS rate was 100% in the NCHTT group and 76.4% in the NAC only group (P = 0.014) (Fig. 1) . During follow-up, only three patients died and the 3-year OS rate was 100% in the NCHTT group and 89.3% in the NAC only group (P = 0.149) (Fig. 2) . 
DISCUSSION
The results of this study indicate that NCHTT induced higher pCR rates than NAC only in patients with locally advanced breast cancer. BCS was more frequently performed in the NCHTT group than in the NCT only group and 3-year RFS rate was significantly higher in the NCHTT group. In comparison with the results from western countries, we could observe a similar benefit from NCHTT.
NAC has become a standard therapy to treat patients with locally advanced breast cancer [8, 13] . The primary goals of NAC are to increase the rate of BCS and to predict prognosis through the response of the tumor to the treatment [8, 14] . NAC can reduce tumor size, which increases the rate of BCS and in some cases has the effect of prolonging OS. In addition, it improves the rates of operability in previously inoperable patients, can treat early stages of micrometastasis before the presence of chemo-resistant cell lines, reduces the risk of recurrence by preventing seeding during surgery and can predict further therapeutic efficacy of chemotherapeutic agents. Conversely, due to its downstaging effects, it can lead to therapeutic confusion due to the diminishment of traditional prognostic factors such as tumor size, axillary metastatic lymph node numbers, and histologic grading which are needed to assess patients for systemic treatment and overtreatment who may benefit by surgical intervention alone.
Although there are no clinical practice guidelines for thesurgery.or.kr NAC, it is more frequently used as a preliminary treatment for patients undergoing surgery than as pretreatment for locally advanced breast cancer.
The HER is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands and a potent mediator of normal cell growth and development [15] . This family of re- exclude those who will not benefit from this therapy.
Trastzumab binds to the extracellular domain of HER2.
Several mechanisms of action underlie the antitumor effects of trastuzumab. Trastuzumab blocks HER2-activated cell signaling, thereby reducing cell proliferation and restoring a capacity for apoptosis by inhibiting the PI3K/Akt pathway [17, 18] , which increases cellular sensitivity to chemotherapy and radiotherapy [19] . It has also been shown to prevent the formation of p95 HER2 (a truncated, active form of HER2), which may lead to inhibition of tumor development [17] . Finally, trastuzumab has been shown to inhibit HER2 regulated angiogenesis and leads to antibody-dependent cell-mediated cytotoxicity and triggers the activation of natural killer cell-mediated apoptosis [17, 20] . Trastuzumab is now the standard therapy used in the adjuvant setting.
Pertuzumab is a humanized monoclonal antibody that binds to an epitope in domain II, the dimerization domain of the HER2 receptor extracellular domain, which is a region of HER2 distinct from the domain IV binding site of trastuzumab [21] . Pertuzumab inhibits HER2 dimerization by preventing HER2 from pairing with other HER receptors, including HER3 [22] . Lapatinib is a dual inhibitor event-free survival rate at three years was significantly better in the chemotherapy plus trastuzumab group compared to chemotherapy alone: 71% versus 56%, respectively (HR, 0.59; P = 0.013); the pCR rate was also significantly higher in the chemotherapy plus trastuzumab group than the chemotherapy only group: (38% vs. 19%, respectively P = 0.001) [24] . In the phase III GeparQuattro trial, 1,509 patients with operable or locally advanced tumors were randomized to receive NAC with four cycles of epirubicin/cyclophosphamide followed by four cycles of docetaxel, with or without capecitabine [25] . The 445 HER2 positive patients enrolled also received trastuzu-mab 6 mg/kg (with a loading dose of 8 mg/kg) every 3 weeks during all chemotherapy cycles. The pCR rate in the HER2 positive subset was 31.7% with no relevant early toxicity observed.
In conclusion, we found that patients treated with
NCHTT experienced higher pCR rates, more breast conserving rates and lower RFS rates compared to patients treated with NAC only. Unfortunately, we have few cases with HER2 amplified locally advanced breast cancer who were treated surgically after NAC. For various survival benefits, additional studies with a larger patient enrollment are required to identify survival differences between
NCHTT and NAC alone with the same chemotherapy regimen.
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